AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.800
-0.080 (-2.78%)
At close: Dec 5, 2025, 4:00 PM EST
2.779
-0.021 (-0.75%)
After-hours: Dec 5, 2025, 7:51 PM EST
AC Immune Revenue
AC Immune had revenue of 939.00K CHF in the quarter ending September 30, 2025, a decrease of -96.32%. This brings the company's revenue in the last twelve months to 4.37M, down -89.33% year-over-year. In the year 2024, AC Immune had annual revenue of 27.31M with 84.51% growth.
Revenue (ttm)
4.37M CHF
Revenue Growth
-89.33%
P/S Ratio
51.31
Revenue / Employee
25,419 CHF
Employees
172
Market Cap
277.04M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ACIU News
- 4 weeks ago - AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 6 weeks ago - First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine - GlobeNewsWire
- 4 months ago - AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 7 months ago - AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 8 months ago - AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - GlobeNewsWire
- 9 months ago - AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 - GlobeNewsWire
- 9 months ago - AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 1 year ago - AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients - Benzinga